In early arthritis (RA) pts there is no value in measuring for IgA-ACPA or IgA-RF, as there presence doesnt provide more than IgG-ACPA. In tREACH trial IgA-ACPA present in 23% & overlaped w/ IgG-ACPA in 94% (w/ IgM-RF in 90%). https://t.co/d8Xc4GBfEt https://t.co/qvujVx0RFf

CT angio in 75 pts w/ Takayasu arteritis (40 w/ cDMARDs, 35 biologics) showed reduced arterial thickness in 73% (31% w/ >25% decr in wall thickness). 1st immunosuppressives (p= 0.012) & bDMARDs(p= 0.026) reduced art. wall thickness (relative to cDMARDs) https://t.co/16eGmgVoWr https://t.co/AyNyT7FsYZ

FDA adverse event study of JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://t.co/BmNPk6zN6o https://t.co/fbzHQmPmH5

Psoriatic Arthritis Topic Panel: EULAR 2024 Dr. Jack Cush moderates this topic panel with Drs. Eric Ruderman, Peter Nash and Antoni Chan. https://t.co/XUFgUUqBu2 https://t.co/08TPtQWBvx

EULAR 2024 Recommendations on Reproductive Health https://t.co/QuXQlpQv8O https://t.co/nHC7LOLLl8

ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations https://t.co/abcs8RwJ5J https://t.co/wLOq4bK7qQ

ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI? https://t.co/J4aE4jxNb0 https://t.co/b6axwp4Tuw

ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update https://t.co/iccSFuAogX https://t.co/ORzwvDKqVo

ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes https://t.co/46g8ek286u https://t.co/FEFq4vkiPk

ICYMI: 9 Facts about Leflunomide Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. https://t.co/WseVa589Fg. https://t.co/K4u00MbwEb

ICYMI: JAMA: SLE Review https://t.co/GJJSOYZru2 https://t.co/mCgWy27yPr

ICYMI: BSR Guideline on Management of Sjogren’s Syndrome https://t.co/MMG3NmCeDl https://t.co/zKlR8jOkLD